Concepedia

Michael Wenger

MW

Statistics

Publications

51

Citations

7K

H-Index

31

Active since

1993

Affiliations

Roche (Switzerland)(Current)

Universität Ulm

University Hospital Cologne

University of Cologne

Centre Hospitalier Universitaire de Lille

Michael Wenger is an author at Roche (Switzerland) specializing in cancer immunotherapy, oncology, and medicine.

Publications per year

1993–2019

51

Publications

51

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

Valentin Goede, Kirsten Fischer, Raymonde Busch et al. · New England Journal of Medicine · 2014 · 1.5K citations · Full text

Pharmacy, Hematology, Pharmacotherapy +16

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 788 citations · Full text

Medicine, Immunology, Oncology +14

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka et al. · Blood · 2014 · 507 citations

Medicine, Genetics, Oncology +17

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

Tadeusz Robak, Anna Dmoszyńska, Philippe Solal‐Céligny et al. · Journal of Clinical Oncology · 2010 · 475 citations · Full text

Medicine, Immunology, Oncology +16

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

Sebastian Böttcher, Matthias Ritgen, Kirsten Fischer et al. · Journal of Clinical Oncology · 2012 · 452 citations

Medicine, Hematology, Oncology +15

1–5 of 51